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Abstract. 
In Taiwan, gastric cancer ranked fifth in total cancer mortality in 2012. Although the 
number of gastric cancer cases has declined in recent decades, it is still the second leading 
cause of cancer mortality worldwide. Therefore, more potential molecular targets and thera-
peutic options for gastric cancer treatment are urgently needed. The overexpression of COX-2 
has been shown to be highly associated with metastasis, invasion and angiogenesis of gastric 
cancer. A positive correlation between COX-2 and c-Met (or Jagged1) expression also has 
been found in gastric cancer. Moreover, several studies indicated that hepatocyte growth fac-
tor (HGF)/c-Met and Jagged1/Notch1 pathways can up-regulate COX-2 expression, resulting 
in increased cell growth, migration and invasion in gastric cancer cells. Recently, various 
monoclonal antibodies or receptor tyrosine kinase inhibitors have been designed to target 
HGF/c-Met pathway and have shown potentials for gastric cancer therapy in clinical trials. In 
this article, we have summarized the molecular mechanisms of HGF/c-Met/COX-2 and Jag-
ged1/Notch1/COX-2 pathways, and the latest target therapies for gastric cancer. 
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中文摘要 
  在 2012 年的台灣，胃癌在所有癌症死亡率中排名第五位。雖然在最近的數十年間，
胃癌的病患數量逐年遞減，但其在全世界的癌症死亡率中仍是排名第二。因此，迫切地
需要發展更多具有潛力的分子標靶和治療方式來治療胃癌病患。臨床上，COX-2 的大量
表現與胃癌的轉移、侵犯和血管新生有高度地關係。在胃癌中也發現 COX-2 和 c-Met (或
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 Jagged1)的表現量呈現正相關。在許多研究中也指出，HGF/c-Met 和 Jagged1/Notch1 路
徑能促進 COX-2 的表現，進而促進胃癌細胞的生長、移動和侵犯。最近，針對 HGF/c-Met
路徑已設計有許多單株抗體或受體酪氨酸激酶抑制劑，且在許多臨床試驗顯示出有治療
胃癌之潛力。因此，此文章整合了 HGF/c-Met/COX-2 和 Jagged1/Notch1/COX-2 路徑的
分子機制，以及最新的胃癌標靶治療。 
關鍵字: 肝細胞生長因子、c-Met、Jagged1、Notch1、COX-2、胃癌 
INTRODUCTION 
Gastric cancer is one of the most common cancers 
worldwide, with 989,600 new cases reported annually 
and causing 738,000 deaths per year [1]. Additionally, 
it accounts for eight percent of all new cancers. In 
2010, approximately 21,000 patients were diagnosed 
with gastric cancer in the United States, and about 
10,570 patients were expected to die from the disease 
[2]. In Taiwan, gastric cancer is the fifth leading cause 
of cancer mortality [3]. Although the total number of 
gastric cancer cases has declined in recent decades, it 
is still the second leading cause of cancer mortality in 
the world [4]. Therefore, investigation of potential 
molecular targets and treatment options is essential to 
help prolong the survival of gastric cancer patients. 
More than 95% of gastric cancer malignancy aris-
es from adenocarcinomas [5]. According to the World 
Health Organization (WHO), gastric tumors can be 
histologically classified into four types: tubular ade-
nocarcinoma, papillary adenocarcinoma, mucinous 
adenocarcinoma, and signet-ring cell carcinoma. The 
most widely used histological classification system is 
the Lauren classification system, which divides ade-
nocarcinomas into intestinal and diffuse types. In 
Taiwan, the ratio of intestinal type to diffuse type was 
1.2 [6]. It is well-known that intestinal and diffuse 
subtypes have different pathogenic bases [7,8]. In the 
intestinal type of gastric cancer, tumor cells are 
well-differentiated and adhere to each other. The in-
testinal type tumor cells tend to arrange cohesive neo-
plastic cells forming gland-like tubular structures. On 
the other hand, the diffuse type tumor cells lack adhe-
sion molecules which allow them to invade nearby 
tissues without the formation of tubules or glands. The 
diffuse type has mutation of E-cadherin gene that re-
sults in the loss of adhesion in cancer cells [9]. Be-
cause E-cadherin is a key cell surface protein for es-
tablishing intercellular connections and maintaining 
the organization of epithelial tissues, the loss of this 
protein tends to change cancer cells morphology from 
epithelial type to mesenchymal type. Gastric cancer 
types and the molecular changes in gastric cancer cells 
play important roles in tumor metastasis and prognosis 
of patients with gastric cancer.  
Interestingly, it has also been found that chronic 
infection of Helicobacter pylori (H. pylori) causes 
down-regulation of E-cadherin expression by CagA in 
the intestinal type cancer cells [10]. In vitro and in 
vivo studies found that H. pylori infected AGS and 
MKN-28 human gastric adenocarcinoma cells had 
elevated COX-2 mRNA level through cag pathogenic-
ity island (cagPAI) activation of the MEK/Erk path-
way [11]. The H. pylori-induced overexpression and 
activation of COX-2 result in increased synthesis of 
prostaglandins, thus promoting cancer cells to prolif-
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 erate and decrease apoptosis [12]. H. pylori infection 
in gastric epithelial cells also resulted in activation of 
microsomal PGE synthase-1 (mPGES-1), which is a 
PGE2 converting enzyme functionally coupled with 
COX-2. As a result, COX-2 expression plays an im-
portant role on the gastric carcinogenesis after H. py-
lori infection [13]. On the other hand, H. pylori mod-
ulated the c-Met downstream signaling transduction 
and enhanced the mitogenic response of AGS cells 
[14]. H. pylori infection also increased the invasion 
ability on AGS cells through activation c-Met, and the 
effect could be inhibited by c-Met antagonist NK4 
[15].  
Recently, it has been found that the Notch1 ligand 
delta-like 1 (DLL-1) was up-regulated by H. pylori 
infection [16]. COX-2 is also on the downstream sig-
naling pathway of Notch [17,18]. Moreover, COX-2 
expression has been observed in the epithelial lining 
of the stomach at different stages of H. pylori-related 
gastric carcinogenesis from chronic active gastritis to 
atrophic gastritis and intestinal metaplasia, and finally 
to gastric cancer [13]. These observations suggest that 
COX-2 expression is not only overexpressed in gastric 
cancer but also involved in the initiation and progres-
sion of gastric cancer.  
 
COX-2 AND PROSTAGLANDIN- 
RELATED FACTORS 
COX-2 is closely involved in tumorigenesis of 
gastrointestinal cancers. The expression of COX-2 has 
been found to be higher in gastric cancer tissues than 
in normal gastric tissues, and is also related to cancer 
metastasis and invasion [19]. COX-2 is a COX isoen-
zyme that catalyzes arachidonic acid into prostaglan-
dins, such as prostaglandin E2 (PGE2) [20] and 
15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) [21]. 
COX-2 enhanced the secretion of PGE2 and up-   
regulated the expressions of PGE2 receptors EP2 and 
EP4 in the small intestinal and colonic polyps [22]. 
Overexpression of COX-2 transforms the surround-
ings of tumor cells into a pro-inflammatory microen-
vironment contributing to tumor development, growth, 
and progression [23]. For instance, increased COX-2 
expression promoted the transition of premalignant 
cells to malignant cells by inducing reactive oxygen 
species (ROS) and lipid peroxide-induced DNA muta-
tions. Using rat intestinal epithelial cells (RIES cells) 
transfected with COX-2 as an experimental model, it 
was found that increased expression of COX-2-   
mediated lipid peroxidation elevated PGE2 and 15(S)- 
hydroperoxyeicosatetraenoic acid (15(S)-HPETE). In-
creased COX-2 expression can further augment 
15(S)-HPETE levels leading to DNA damage in cells, 
and this process can be reduced by the specific COX-2 
inhibitor NS-398 [24]. These results together with the 
observation of increased expression of COX-2 and 
PGE2 in colorectal cancer cells [25], breast cancer 
cells [26] and gastric cancer cells [27] suggest that 
COX-2 inhibitors may have potential in chemopre-
vention of gastrointestinal carcinogenesis. 
In addition to PGE2 synthesis, PGE2 degradation 
also plays an important role in gastric carcinogenesis. 
The 15-hydroxyprostaglandin dehydrogenase [NAD+] 
(15-PGDH) which catalyzes the rate-limiting step of 
prostaglandin catabolism is found to be down-    
regulated in human gastric cancer tissues and is the 
key enzyme in prostaglandin degradation [21]. It has 
been reported that the proliferation rate of gastric 
cancer cells increased as 15-PGDH siRNA was trans-
fected [28]. Furthermore, the 15-PGDH is highly ex-
pressed in normal colon mucosa, but the expression is 
ubiquitously lost in human colon cancers [29]. In ad-
dition, IL-6 has been found to increase the expression 
of 15-PGDH leading to increased growth of andro-
gen-sensitive prostate cancer cells [30]. ApcMin+/- 
mice provided an interesting model for the low ex-
pression level of the 15-PGDH enzyme that caused 
malignancy in intestinal adenomas [31]. Colonic can-
cer studies showed that treatment of mice with 
celecoxib (COX-2 inhibitor) and 15-PGDH would 
reduce the PGE2 level and leading to decreased tumor 
volume and tumor size. Otherwise, low levels of 
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 15-PGDH might be resistant to the colon tumor pre-
vention activity of celecoxib by increasing PGE2 [32]. 
These results together suggest that 15-PGDH might be 
a potential therapeutic target for colon cancer and gas-
tric cancer. 
Wnt pathways have been reported to play an im-
portant role in tumorigenesis of gastric cancer [33]. 
Activation of the Wnt/β-catenin signaling pathway has 
been found to increase COX-2 expression in gastric 
cancer cells [34]. When using K19-Wnt1 transgenic 
mice expressing Wnt1 in the gastric mucosa by the 
keratin 19 promoter as an in vivo model to examine 
carcinogenesis, there was a significant suppression of 
epithelial differentiation and presence of small 
pre-neoplastic lesions consisting of undifferentiated 
epithelial cells. On the other hand, using the 
K19-C2mE mice with COX-2 and mPGES-1 genes 
over-expressed in the forestomach and glandular 
stomach to examine the effect of PGE2 on gastric tis-
sue, it was found that the PGE2 level is approximately 
double that of the wide-type mice [35]. Interestingly, 
the levels of COX-2 and mPGES-1 expression in the 
K19-Wnt1/C2mE mice were higher than that of the 
K19-Wnt1 or K19-C2mE mice. The increase of 
COX-2 and mPGES-1 expression correlated with the 
increased of tumor cells proliferation, angiogenesis 
and cancer progression in the K19-Wnt1/C2mE mice. 
These results indicated that activation of both Wnt and 
PGE2 signaling pathways can synergistically enhance 
formation of dysplastic gastric tumors [36]. The in-
flammation related factors such as COX-2, 15-HETE, 
PGE2, EP4, mPGES-1 and Wnt seem to be closely re-
lated to carcinogenesis of gastric cancer and have the 
potential to be targets for gastric cancer therapy. 
 
HEPATOCYTE GROWTH FACTOR 
AND C-MET RECEPTOR IN  
GASTRIC CANCER 
HGF is a 145-kilodalton plasminogen-like tyrosyl 
phosphoprotein. HGF/scatter factor is the ligand for 
c-Met receptor. Binding of HGF to the β subunit of 
c-Met receptor can activate c-Met and trigger the ac-
tivity of its downstream factors [37]. The c-Met re-
ceptor is a member of the receptor tyrosine kinase 
(RTK) family. The signals mediated by RTKs are es-
sential for cell development and maintenance of the 
cells of multicellular organisms. 
Once HGF binds to c-Met, it triggers a conforma-
tional change that activates the downstream signaling 
pathway [38]. Therefore, the c-Met RTKs are phos-
phorylated that activate specific proteins such as Src, 
Src homology 2 (SH2), growth factor receptor-bound 
protein 2 (Grb2), Gab1, and phosphatidylinositol 
3-kinase (PI3K) signal transduction [39]. In the rat 
gastric epithelial cells, it has been reported that 
HGF/c-Met signaling would trigger COX-2 activation 
through Erk2 signal pathway [40]. In addition, the 
Grb2 activate RAS/ErK pathway through binding to 
c-Met docking site and phosphorylated Y1356 trans-
duction. Activation of the RAS/ErK pathway is in-
volved in metastasis of cancer cells [41]. These results 
show that activation of c-Met by HGF can stimulate 
different pathways related to cancer progression. 
The c-Met activation has been found to be associ-
ated with drug resistance [42], metastasis [43], migra-
tion and invasion [44] in various tumors. It has been 
reported that the c-Met siRNA could decrease prolif-
eration, motility, and invasive ability [45] of human 
hepatocellular carcinoma (HCC) cell line MHCC97-H. 
NK4 is a competitive inhibitor of HGF/c-Met. The 
binding of NK4 to c-Met receptor can block the tyro-
sine phosphorylation of c-Met, and inhibit the HGF- 
mediated proliferation and migration of colon cancer 
cells [46]. In vivo studies showed that adenoviral-  
mediated NK4 gene transduction in nude mice could 
suppress tumor growth [47] and peritoneal metastases 
from gastric cancer [48]. Besides, HGF could increase 
the production of PGE2 in human gastric carcinoma 
TMK-1 cells. HGF up-regulated the COX-2 expres-
sion in the SC-M1 gastric adenocarcinoma cells and 
the COX-2 expression was associated with c-Met ac-
tivation in gastric tumors [49]. Monoclonal antibodies  
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Figure 1. Potential target therapies in gastric cancer. The mechanisms of Helicobacter pylori, 
hepatocyte growth factor (HGF)/c-Met, and Jagged1/Notch1 pathways on cell migra-
tion and proliferation are described. Monoclonal antibodies and receptor tyrosine ki-
nase inhibitors, designed to target HGF/c-Met pathway in gastric cancer, are indicated 
by respective rectangles 
 
 
designed to target HGF/c-Met in cancer cells, such as 
Rilotumumab (targeting on HGF), and RTK inhibitors 
such as Tivantinib and Foretinib have potential roles 
in gastric cancer therapy (Figure 1) [50]. Recent study 
showed that an antibody DN30 bound to the extracel-
lular domain of c-Met receptors could reduce gastric 
tumor growth, invasion and metastasis [51]. Moreover, 
clinical studies revealed that high serum HGF concen-
tration [52] and high HGF mRNA expression [53] 
were associated with poor survival in gastric cancer 
patients. Similar to the above studies, it is reported 
that c-Met expression in patients who had liver me-
tastasis from gastric cancer was higher than in those 
without such metastasis [43]. In conclusion, the 
HGF/c-Met pathway plays an important role in the 
progression of gastric cancer and is a potential target 
for treatment of gastric cancer.  
 
THE NOTCH RECEPTOR AND 
GASTRIC CANCER 
Notch receptor is a transmembrane receptor which 
has four different subtypes, Notch1-4. The ligands of 
Notch are Jagged1-2, and Delta-like-1, 3 and 4. Notch 
is activated by ligand binding and cleaved by 
γ-secretases with the product of Notch intracellular 
domain (NICD). NICD enters the nucleus to activate 
the nuclear effector CBF-1, Su(H) and Lag-1 (CSL). 
The downstream target genes, such as HES-1 are 
up-regulated by CSL-dependent pathway [54]. 
Notch, as an oncogene, was first identified in the 
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 human T-cell neoplasia [55]. Notch activation was 
also found to be associated with other diseases like 
Alzheimer’s disease [56], Alagille’s syndrome [57], 
Down syndrome [58], breast cancer [59] and gastric 
cancer [16]. Besides, it has been reported that activa-
tion of c-Met would enhance Notch signaling pathway 
and further reduce the c-Met promoter activation 
through HES-1 activation in MDA-MB-435 cancer 
cells [60]. Recent studies showed that Lfng controls 
Notch signaling in many developing tissues and is one 
of three Fringe genes in mammals. The reduction of 
Lfng expression results in expression of Jagged/Notch 
luminal progenitor signals and activation c-Met/  
caveolin basal-type signaling to promote basal-like 
breast cancers [61]. In prostate cancer cells, treatment 
with HGF would up-regulate Jagged1, Notch1, DLL4 
and HES-1 gene expression, but it didn’t affect Notch2, 
3 and Jagged2 [62]. The activation of Notch signaling 
pathway would trigger by HGF/c-Met signaling 
through Erk pathway in head and neck squamous cell 
carcinoma (HNSCC) [63]. Activation of Notch1 sig-
naling pathway up-regulated Twist expression and 
STAT phosphorylation leading to growth, migration 
and invasion of gastric cancer cells [64]. In SC-M1 
gastric cancer cells, activation of Notch1 and Notch2 
signaling enhanced COX-2 expression and elevated 
cell migration and invasion abilities [17,18]. In gastric 
cancer SGC7901 cells, the siRNA of Jagged1 and 
DLL4 would inhibit cells migration and proliferation 
[65]. These findings clearly demonstrated that the 
Jagged/Notch signaling pathway plays an important 
role in the cancer cells proliferation, migration and 
invasion. More importantly, the interaction between 
HGF/c-Met and Jagged1/Notch1 signaling pathways 
in gastric cancer is worthy of further investigation. 
 
THE POTENTIAL TARGET 
THERAPY IN GASTRIC CANCER 
Met and Notch inhibitors are currently undergoing 
additional testing in clinical trials for target therapy of 
cancer. It has been reported that treatment of a 
chemo-refractory gastric cancer patient with Met 
monoclonal antibody resulted in a complete response 
for 2 years in a phase I clinical trial [66]. In addition, 
decrease of tumor size was observed in two of four 
patients with c-Met amplified esophagogastric adeno-
carcinoma after treatment with Crizotinib in a phase I 
study [67]. On the other hand, anti-notch receptor 
monoclonal antibodies and agents inhibiting the 
γ-secretase to block cleavages of Notch receptors have 
also entered the early phases of clinical trials for 
treatment of various cancers [68]. These studies 
clearly showed that c-Met and Notch receptor signal-
ing pathways have potential for target therapy for gas-
tric cancer patients.  
Gastric cancer is associated with Cag-A positive H. 
pylori infection. Eradication of H. pylori alone may 
reduce the risk of gastric cancer, especially before at-
rophy and intestinal metaplasia. A previous study 
showed that regular use of NSAIDs could reduce the 
incidence of gastric cancer in H. pylori-infected 
patients [69]. Both HGF/c-Met and Jagged1/Notch1 
pathway could up-regulate COX-2 expression, result-
ing in tumor growth, migration and invasion. Conse-
quently, COX-2 inhibitors such as aspirin have been 
found to prevent colorectal adenomas in patients with 
previous colorectal cancer [70]. Since COX-2 inhibi-
tors reduced gastric cancer in animal models and 
overexpression of COX-2 has been found in 
pre-malignant lesion and gastric cancer, further ran-
domized clinical trials with inhibitors for MET/Notch 
-COX-2 signaling pathway are worthy of investigation 
in gastric cancer patients. 
 
CONCLUSIONS 
HGF/c-Met, Jagged1/Notch1 and related signaling 
molecules might be potential therapeutic targets in 
gastric cancer treatment. Consequently, the expression 
of HGF/c-Met, Jagged/Notch as well as the COX-2 
expression and the production of PGE2 can be consid-
ered as molecular targets for therapy in patients with 
advanced gastric cancer. 
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